At the FDA/Xavier PharmaLink conference in March 2017, FDA National Expert Investigator Robert Tollefsen presented a case study on a pharma company with compliance problems, and led a group discussion with the audience on what the appropriate actions would be for the company to undertake, given the circumstances.
At the 2017 FDA/Xavier University PharmaLink conference Robert Tollefsen, an FDA National Expert Investigator – Drugs/Computers, Pharmaceutical Inspectorate/Level III Certified in Drugs, Medical Products and Tobacco Program Operations Branch, and Dell Moller, FDA Cincinnati District Supervisory Investigator, presented FDA’s top ten drug GMP inspection citations for FY 2016. This article includes a brief comment/analysis on the findings and additional information regarding inspection trends and other inspection findings.
Dr. Marla Phillips, Xavier Health Director, spoke at the 15th Annual Cold Chain GDP & Temperature Management Logistics Global Forum.
The Xavier AI Summit was a featured topic on Cincinnati Edition, a live interview program on Cincinnati Public Radio station WVXU, 91.7 FM.
Xavier Health Director, Dr. Marla Phillips, presented at the 121st Association of Food and Drug Officials (AFDO) conference, June 19, 2017, in Houston.
IBM Watson Health and Xavier University announce a partnership to further the use of artificial intelligence within the healthcare industry.
Director of Xavier Health, Dr. Marla Phillips, was a featured guest columnist for Pharmaceutical Online.
In support of FDA’s intent to allocate its resources based on risk, Xavier University and PwC launched a Metrics Initiative in August 2014 to identify product quality risk metrics linked to patient safety that could be viewed during an inspection.